Psoriasis

Recent developments regarding ESK-001, an oral, highly selective TYK2 inhibitor being developed for moderate-to-severe plaque psoriasis, were presented at EADV 2024. TYK2 plays a crucial role in the cell signalling through cytokines such as IL-23 and IL-12, both of which are key players in the pathogenesis of psoriasis. ESK-001 aims to inhibit these pathways to offer an effective treatment option for patients. The STRIDE (NCT05600036) study, a phase 2 randomized, placebo-controlled trial, has already shown promising, dose-dependent efficacy, and the ongoing open-label extension study is assessing its long-term safety and effectiveness.

GUIDE is a phase 3b randomized, parallel-group, double-blind trial investigating guselkumab for the treatment of moderate-to-severe psoriasis (NCT03818035). We were delighted to speak with Prof. Knut Schäkel (University Hospital Heidelberg, Germany) to discuss the clinical data already supporting GUS from GUIDE 1 and 2, and the rationale, methodology and findings from GUIDE part 3, which were presented at EADV. The abstract 'Treatment-free period of more than 1 year in guselkumab super responders with short disease duration of psoriasis: withdrawal data from the GUIDE trial' (Abstract N°: 2042) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions What were the aims, design and eligibility criteria of the Phase 3b GUIDE trial? (0:16) What data from GUIDE 1 and 2 already supports early intervention with GUS? (1:28) Could you describe the rationale and methodology of GUIDE part 3? (2:19) What were the clinical endpoints and how well were these achieved? (3:10) What significance do these findings have in terms of maintenance of response following GUS withdrawal? (4:06) Disclosures: Knut Schäkel has been an advisor and/ or received speakers' honoraria and/ or received grants and/ or participated in clinical trials of the following companies: AbbVie, Almirall, Antabio, Boehringer Ingelheim, Celgene, Eli Lily, Galderma, Janssen-Cilag GmbH, LEO Pharma, Novartis, Pfizer and UCB Pharma. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.  Click here for more content on psoriasis & for further EADV 2023 highlights visit here.

The POETYK PSO long term extension (LTE) study investigated the efficacy and safety of deucravacitinib at 3 years in patients with plaque psoriasis (NCT04036435). touchDERMATOLOGY were delighted to speak with Dr. Leon. Kircik around the mechanism of action of deucravacitinib, the clinical data supporting its use in clinical practice, and the long term efficacy and safety data from the POETYK PSO LTE. This information is provided solely by Touch Medical Media and is independent of any sponsorship or affiliation with the European Academy of Dermatology & Venereology (EADV). Questions What is the mechanism of action of deucravacitinib? (0:21) What clinical evidence already supports the use of deucravacitinib? (0:41) What were the findings from the POETYK PSO long-term extension trial? (1:25) How will these insights optimise the use of deucravacitinib in plaque psoriasis? (2:10) In which patients is deucravacitinib most beneficial? (2:43) Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Tapinarof cream 1% once daily, a topical aryl hydrocarbon receptor (AhR)-modulating agent was recently approved by the FDA for the treatment of plaque psoriasis. touchIMMUNOLOGY were delighted to speak with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) to learn more about the unmet needs in the treatment of plaque psoriasis, the rationale […]

Effisayil 1 (NCT03782792) was a randomised, double-blind, placebo-controlled phase 2 study that investigated the efficacy and safety of spesolimab in generalized pustular psoriasis (GPP). touchIMMUNOLOGY were delighted to speak with Dr. Claudia De La Cruz (Clínica Dermacross, Santiago, Chile) to discuss the aims, design and findings from Effisayil 1 and the impact spesolimab has already […]

Personalised medicine utilises biomarkers to predict patient outcomes and responses to treatment, ensuring that patients get the most effective treatment quicker. We were delighted to speak to Expert Faculty member Dr. William Damsky (Yale School of Medicine, New Haven, CT, USA) around the recent advances made in biomarkers and targeted therapies for inflammatory skin diseases, […]

Ixekizumab is a humanized monoclonal antibody currently approved in patients with moderate-to-severe plaque psoriasis. We caught up with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA) to discuss the aims, design, inclusion criteria and main findings of a post-hoc analysis conducted on trials studying the use of ixekizumab in adult and paediatric patients […]

Palmoplanter psoriasis occurs in 12–16% of patients with psoriasis in the USA.1 These patients report greater health-related quality of life impairments than patients with other forms of psoriasis.1 Ixekizumab (Eli Lilly and Company, Indianapolis, IN, USA) is an interleukin-17 antagonist that has been approved for use in moderate-to-severe plaque psoriasis and psoriatic arthritis.2  A poster […]